litlas
ログインアカウント作成

Mark J. Ratain

1986–2025 年に発表

156
論文数
28,041
被引用数
90
h 指数
148
i10 指数

被引用数

Mark J. Ratain の年別被引用数1956 年: 被引用 1 件1977 年: 被引用 1 件1987 年: 被引用 1 件1988 年: 被引用 2 件1989 年: 被引用 2 件1990 年: 被引用 8 件1991 年: 被引用 6 件1992 年: 被引用 8 件1993 年: 被引用 10 件1994 年: 被引用 8 件1995 年: 被引用 13 件1996 年: 被引用 10 件1997 年: 被引用 13 件1998 年: 被引用 36 件1999 年: 被引用 41 件2000 年: 被引用 69 件2001 年: 被引用 77 件2002 年: 被引用 122 件2003 年: 被引用 114 件2004 年: 被引用 117 件2005 年: 被引用 190 件2006 年: 被引用 220 件2007 年: 被引用 246 件2008 年: 被引用 217 件2009 年: 被引用 274 件2010 年: 被引用 274 件2011 年: 被引用 299 件2012 年: 被引用 347 件2013 年: 被引用 296 件2014 年: 被引用 300 件2015 年: 被引用 272 件2016 年: 被引用 237 件2017 年: 被引用 186 件2018 年: 被引用 194 件2019 年: 被引用 639 件2020 年: 被引用 615 件2021 年: 被引用 618 件2022 年: 被引用 466 件2023 年: 被引用 296 件2024 年: 被引用 438 件2025 年: 被引用 228 件2026 年: 被引用 5 件1957〜1976 年は被引用が無いため表示していません1978〜1986 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,364 件、この内訳の 33.4%中国: 引用元論文 756 件、この内訳の 7.5%イギリス: 引用元論文 609 件、この内訳の 6%ドイツ: 引用元論文 477 件、この内訳の 4.7%イタリア: 引用元論文 445 件、この内訳の 4.4%カナダ: 引用元論文 401 件、この内訳の 4%オランダ: 引用元論文 377 件、この内訳の 3.7%フランス: 引用元論文 366 件、この内訳の 3.6%日本: 引用元論文 302 件、この内訳の 3%スペイン: 引用元論文 268 件、この内訳の 2.7%オーストラリア: 引用元論文 261 件、この内訳の 2.6%スイス: 引用元論文 205 件、この内訳の 2%
0%33.4%その他 22.4%

機関

分野

  • Medicine54%
  • Biochemistry, Genetics and Molecular Biology24.8%
  • Pharmacology, Toxicology and Pharmaceutics6.7%
  • Economics, Econometrics and Finance4.7%
  • Immunology and Microbiology2.2%
  • Mathematics1.8%
  • その他5.8%

トピック

  • Lung Cancer Treatments and Mutations5.4%
  • Cancer Genomics and Diagnostics3.7%
  • Lung Cancer Research Studies3.3%
  • Pharmacogenetics and Drug Metabolism3%
  • Cancer therapeutics and mechanisms2.7%
  • Cancer Immunotherapy and Biomarkers2.4%
  • その他79.5%

共著者

全論文

検索で開く
  1. Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

    著者: Jonas A. de Souza, Bonnie J. Yap, Kristen Wroblewski, Victoria Blinder, Fabiana S. Araújo, Fay J. Hlubocky, Hyung J. Cho, Jeremy O’Connor, Bruce Brockstein, Mark J. Ratain, Christopher K. Daugherty, David Cella - Cancer 2016 被引用: 882

  2. The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

    著者: Jonas A. de Souza, Bonnie J. Yap, Fay J. Hlubocky, Kristen Wroblewski, Mark J. Ratain, David Cella, Christopher K. Daugherty - Cancer 2014 被引用: 649

  3. Tumour heterogeneity in the clinic

    著者: Philippe L. Bédard, Aaron R. Hansen, Mark J. Ratain, Lillian L. Siu - Nature 2013 被引用: 1,230

  4. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

    著者: Jason J. Luke, Jeffrey M. Lemons, Theodore Karrison, Sean P. Pitroda, J.M. Melotek, Yuanyuan Zha, Hania Al‐Hallaq, Ainhoa Arina, Nikolai N. Khodarev, Linda Janisch, Paul J. Chang, Jyoti D. Patel, Gini F. Fleming, John W. Moroney, Manish Sharma, Julia White, Mark J. Ratain, Thomas F. Gajewski, Ralph R. Weichselbaum, Steven J. Chmura - Journal of Clinical Oncology 2018 被引用: 587

  5. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    著者: Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2010 被引用: 4,504

  6. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    著者: Daniel Vilarim Araújo, Alastair Greystoke, SE Bates, A. Bayle, Emiliano Calvo, Luís Castelo-Branco, Johann S. de Bono, Alexander Drilon, Elena Garralda, Percy Ivy, Olga Kholmanskikh, Ignacio Melero, George Pentheroudakis, James J. B. Petrie, Ruth Plummer, Santiago Ponce, S. Postel-Vinay, L.L. Siu, Anna Spreafico, Anastasios Stathis, Neeltje Steeghs, Christina Yap, Timothy A. Yap, Mark J. Ratain, Lesley Seymour - Annals of Oncology 2022 被引用: 97

  7. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

    著者: Matthew P. Goetz, Katrin Sangkuhl, Henk‐Jan Guchelaar, Matthias Schwab, Michael A. Province, Michelle Whirl‐Carrillo, W. Fraser Symmans, Howard L. McLeod, Mark J. Ratain, Hitoshi Zembutsu, Andrea Gaedigk, Ron HN van Schaik, James N. Ingle, Kelly E. Caudle, Teri E. Klein - Clinical Pharmacology & Therapeutics 2018 被引用: 324

  8. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

    著者: Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem, Elia Martinez, Mark Kozloff, Bradley Curtis Carthon, R. Donald Harvey, Paul A. S. Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D. Figg, Walter M. Stadler, Mark J. Ratain - Journal of Clinical Oncology 2018 被引用: 181

  9. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors.

    著者: Anthony W. Tolcher, Kyriakos P. Papadopoulos, Amita Patnaik, Drew Rasco, D.Y. Freire Martinez, Debra L. Wood, B. Fielman, Manish Sharma, Linda Janisch, Bob D. Brown, Pankaj Bhargava, Mark J. Ratain - Journal of Clinical Oncology 2015 被引用: 116

  10. Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

    著者: Federico Innocenti, Samir D. Undevia, Lalitha Iyer, Pei Xian Chen, Soma Das, Masha Kocherginsky, Theodore Karrison, Linda Janisch, Jacqueline Ramı́rez, Charles M. Rudin, Everett E. Vokes, Mark J. Ratain - Journal of Clinical Oncology 2004 被引用: 954

  11. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

    著者: Corey C. Foster, Gini F. Fleming, Theodore Karrison, Chih‐Yi Liao, Ami V. Desai, John W. Moroney, Mark J. Ratain, Rita Nanda, Blasé N. Polite, Olwen Hahn, Peter H. O’Donnell, Everett E. Vokes, Hedy L. Kindler, Robyn D. Hseu, Linda Janisch, Julia Dai, Mark D. Hoffman, Ralph R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura, Jason J. Luke - Clinical Cancer Research 2021 被引用: 42

  12. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

    著者: Patricia LoRusso, Mark J. Ratain, Toshihiko Doi, Drew Rasco, Maja J.A. de Jonge, Víctor Moreno, Benedito A. Carneiro, Lot A. Devriese, Adam M. Petrich, Dimple Modi, Susan E. Morgan-Lappe, Silpa Nuthalapati, Monica Motwani, Martin Dunbar, Jaimee Glasgow, Bruno C. Medeiros, Emiliano Calvo - Investigational New Drugs 2022 被引用: 29

  13. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

    著者: Razelle Kurzrock, Steven I. Sherman, Douglas W. Ball, Arlene A. Forastiere, Roger B. Cohen, Ranee Mehra, David G. Pfister, Ezra E.W. Cohen, Linda Janisch, Forlisa Nauling, David S. Hong, Chaan S. Ng, Lei Ye, Robert F. Gagel, John Frye, Thomas Müller, Mark J. Ratain, Ravi Salgia - Journal of Clinical Oncology 2011 被引用: 551

  14. Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer

    著者: Rachel Humphrey, Laura Brockway-Lunardi, Damian Bonk, Kathleen M. Dohoney, James H. Doroshow, Sandra J. Meech, Mark J. Ratain, Suzanne L. Topalian, Drew M. Pardoll - JNCI Journal of the National Cancer Institute 2011 被引用: 136

  15. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    著者: Tim Eisen, T. Ahmad, Keith T. Flaherty, Martin Gore, Stan B. Kaye, Richard Marais, I. Gibbens, Samuel Hackett, Maggie James, Lynn M. Schuchter, Katherine L. Nathanson, Chenjing Xia, Ronit Simantov, Brian Schwartz, Melanie Poulin-Costello, Peter J. O’Dwyer, Mark J. Ratain - British Journal of Cancer 2006 被引用: 636

  16. Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement

    著者: Laura A. Levit, Jeffrey Peppercorn, Alda L. Tam, Jonathan M. Marron, Debra Mathews, Kathryn Levit, Nancy Roach, Mark J. Ratain - Journal of Clinical Oncology 2019 被引用: 53

  17. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

    著者: Mark J. Ratain, Ian F. Tannock, Allen S. Lichter - Journal of Clinical Oncology 2021 被引用: 41

  18. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

    著者: Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain - The Journal of Clinical Pharmacology 2021 被引用: 33

  19. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    著者: Lalitha Iyer, Soma Das, Linda Janisch, Min Wen, Jacqueline Ramı́rez, Theodore Karrison, Gini F. Fleming, Everett E. Vokes, Richard L. Schilsky, Mark J. Ratain - The Pharmacogenomics Journal 2002 被引用: 712

  20. Pharmacogenomics: Challenges and Opportunities

    著者: Dan M. Roden, Russ B. Altman, Neal L. Benowitz, David A. Flockhart, Kathleen M. Giacomini, Julie A. Johnson, Ronald M. Krauss, Howard L. McLeod, Mark J. Ratain, Mary V. Relling, Huijun Z. Ring, Alan R. Shuldiner, Richard M. Weinshilboum, Scott T. Weiss - Annals of Internal Medicine 2006 被引用: 281

  21. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine

    著者: Kathleen M. Giacomini, Sook Wah Yee, Taisei Mushiroda, Richard M. Weinshilboum, Mark J. Ratain, Michiaki Kubo - Nature Reviews Drug Discovery 2016 被引用: 104

  22. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    著者: Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer - Journal of Clinical Oncology 2006 被引用: 1,030

  23. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.

    著者: Harvey M. Golomb, Alice K. Jacobs, A Fefer, Howard Ozer, John F. Thompson, C. Portlock, Mark J. Ratain, David W. Golde, J. W. Vardiman, Jerome S. Burke - Journal of Clinical Oncology 1986 被引用: 236

  24. Cancer pharmacogenomics: strategies and challenges

    著者: Heather E. Wheeler, Michael L. Maitland, M. Eileen Dolan, Nancy J. Cox, Mark J. Ratain - Nature Reviews Genetics 2012 被引用: 220